Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

Houston, TX, April 09, 2026 --

(the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced another publication of a peer-reviewed study in BMC Psychiatry reporting that Nexalin’s DIFS 77.5 Hz high-gamma approach was associated with statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents with non-suicidal self-injury (NSSI). The study also reported measurable changes in brain-network activity and connectivity, providing additional neurophysiological evidence supporting Nexalin’s non-invasive, high-power DIFS technology.

The article, titled, “

,” evaluated six female adolescent patients who received 21 days of 77.5 Hz, 15 mA stimulation using a Nexalin Technology, Inc. device. According to the publication, patients showed statistically significant improvements in depressive symptoms and self-injury behaviors, with benefits persisting through follow-up assessments. The paper further found changes in functional connectivity across emotional-control networks, including Default, Limbic, Salience/Ventral Attention, and Control networks.

Nexalin continues to publish scientific data with neuroimaging and biomarker evidence establishing clinical relevance of its high-power 15 mAmp waveform that supports its DIFS technology. Nexalin’s continued establishment of scientific biomarkers challenges the status quo of all current neurostimulators and the Company believes it positions Nexalin technology to become the world’s leader in non-invasive neurostimulation of the whole brain for the treatment of mental health disorders.

Key findings reported in the publication include:

• Significant improvement in HAMD-24 depression scores after treatment and through follow-up
• Significant reduction in OSIC self-injury scores, including decreases in self-injury thoughts and behaviors
• Improvement in anxiety and sleep quality measures
• All patients met the paper’s predefined clinical response criterion for depression, and 5 of 6 patients (83.3%) met the response criterion for self-injury outcomes
• No significant adverse effects were observed, with only one mild headache reported that resolved quickly

The authors concluded that 77.5 Hz stimulation may alleviate NSSI symptoms in female adolescents by regulating brain activity and functional connectivity in emotional control networks and described the findings as preliminary evidence supporting further investigation in larger randomized controlled trials. The study was accepted on March 10, 2026, and published as an Article in Press in BMC Psychiatry.

David Owens, MD, Chief Medical Officer of Nexalin, said, “This publication is important because it extends the scientific case for Nexalin’s high-gamma DIFS technology into one of the most urgent and difficult-to-treat populations in mental health. What stands out is not just the symptom improvement, but the objective TMS-EEG evidence showing changes in the brain networks associated with rumination, emotional regulation, and self-injurious behavior. We believe these findings further support the underlying mechanism of our 77.5 Hz, 15 mA neurostimulation approach and add to the growing body of peer-reviewed evidence validating Nexalin’s platform.”

Mark White, CEO of Nexalin, added, “We believe publications like this continue to strengthen the scientific and commercial case for Nexalin’s high-power non-invasive DIFS platform. The Nexalin 15 mAmp DIFS technology allows for deeper penetration, which supports higher efficacy and enhanced treatment outcomes in a treatment-resistant population. In a market seeking safer, drug-free alternatives in mental health, each additional peer-reviewed publication helps further validate our technology and broaden its relevance across multiple indications.”

Nexalin believes this publication adds to a growing body of research supporting its DIFS platform as a non-invasive, drug-free approach designed to target dysfunctional brain activity and connectivity, rather than relying solely on subjective symptom reporting. By pairing clinical outcomes with objective neurophysiological measures, the study provides additional support for Nexalin’s strategy of building a differentiated evidence base around its proprietary high-frequency brain stimulation technology. Importantly, this publication adds to recent peer-reviewed and published data that collectively span insomnia and depression (mood), traumatic brain injury and PTSD (military), Alzheimer’s disease (memory), and, most recently, attention deficit hyperactivity disorder (ADHD), further reinforcing the breadth of Nexalin’s platform across multiple high-value CNS indications.

While the BMC Psychiatry paper was a small pilot study without sham control, it is notable for combining reported clinical improvement with electrophysiological evidence suggesting modulation of high-gamma connectivity and emotional-control circuitry. The publication also reports decreased Default network activity, increased Limbic, SalVAttn and Control network activity, and enhanced high-gamma functional connectivity between Control and SalVAttn/Default networks, while noting the findings are preliminary and require validation in larger controlled studies.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All Nexalin's products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes advanced proprietary bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the midbrain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 mA neurostimulation device has been approved in China, Brazil, Oman, and Israel. Additional information about the Company is available at: .